Skip to main content

M16-067 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

NCT03398148

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to evaluate the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

AbbVie

The purpose of this study is to evaluate the efficacy and safety of risankizumab and determine how well it works in subjects with moderate to severe ulcerative colitis.

This study is currently enrolling.